Receptor names describe which signalling target a molecule acts on, not how strong or how safe it is. In metabolic peptide literature you will mainly meet three: the GLP-1 receptor, the GIP receptor and the glucagon receptor. GLP-3 is used informally here as a customer-facing name for retatrutide because it acts at those three named targets; it is not itself a receptor name. GLP-2 is a separate target.
What each name refers to
| Item | Detail |
|---|---|
| GLP-1 receptor | The target of glucagon-like peptide-1 receptor agonists. Semaglutide is described in its official labelling as a GLP-1 receptor agonist. |
| GIP receptor | The target of glucose-dependent insulinotropic polypeptide, a second incretin signal studied alongside GLP-1. |
| Glucagon receptor | A distinct target usually discussed in the context of glucose output and energy expenditure research. |
| “GLP-3” | Not a recognised receptor name. If a listing uses it, treat the description as unreliable. |
Why the count of targets matters in reading
Retatrutide is described in the published phase 2 trial report as an agonist at the GLP-1, GIP and glucagon receptors (three targets), reported in a 2023 randomized, placebo-controlled study of 338 adults over 48 weeks. Receptor activity and clinical outcomes remain separate questions. Jastreboff et al., 2023
Counting targets tells you what a study was designed to interrogate. It does not tell you that more targets produce a better outcome, nor that findings from one molecule transfer to another molecule acting on an overlapping receptor. Every additional target is an additional set of expected and unexpected effects that a trial has to measure.
How the mechanism sentence is usually built
Official semaglutide labelling keeps two effects apart. One is appetite: it states that GLP-1 regulates appetite and calorie intake, that GLP-1 receptors are present in brain regions involved in appetite regulation, and that calorie intake is decreased likely through an effect on appetite. The other is blood glucose: glucose-dependent insulin secretion and reduced glucagon secretion lower blood glucose. Delayed gastric emptying is described separately again. Reduced eating is therefore not presented as a consequence of the insulin and glucagon actions. These are statements from labelling for specific approved formulations, not general claims about any vial sharing an ingredient name. US semaglutide prescribing information
Study context and limits
- Receptor pharmacology explains a proposed pathway; it does not demonstrate an outcome in people.
- Outcome evidence comes from trials with a defined population, comparator, endpoint and duration, for example the 68-week STEP 1 trial of semaglutide in 1,961 adults with overweight or obesity without diabetes, which reported body-weight reduction alongside gastrointestinal adverse effects.
- Approved-medicine labelling and trial reports describe the studied product. They do not describe a research vial sold for laboratory use.
Wilding et al., 2021 (STEP 1) US semaglutide prescribing information
A short reading checklist
- Name the receptor or receptors the source actually says the molecule acts on.
- Check whether the source is a trial report, a regulated label or promotional text.
- Separate mechanism statements from outcome statements in your notes.
- Reject invented receptor names and unnamed “next-generation” claims.
- Never carry a trial result across to a differently manufactured product.
Where the naming confusion comes from
Marketing copy often compresses “acts at three receptors” into a single invented label that sounds like a generation number. Reading the receptor list literally, in the words of the primary source, is the fastest way to notice when a description has drifted away from the underlying science.
Frequently asked
Is there such a thing as a GLP-3 receptor agonist?
No receptor is scientifically named GLP-3. Here, GLP-3 is an informal name for retatrutide, which published research describes as acting at the separately named GLP-1, GIP and glucagon receptors.
Does acting on more receptors mean a stronger effect?
Not automatically. The number of targets describes pharmacology, not effect size or safety. Any comparison needs trials that measured comparable endpoints in comparable populations.
References
Each reference describes a particular study or document. It does not verify any Proof Line Peptides lot, and it does not indicate that a product is authorized for sale in Canada.
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. N Engl J Med. 2023. doi:10.1056/NEJMoa2301972 View source
- Official United States prescribing information for semaglutide injection (Ozempic). United States labelling only; it is not Canadian authorization evidence. View source
- Official United States prescribing information for semaglutide injection 2.4 mg (Wegovy), sections 12.1 and 12.2. United States labelling only; it is not Canadian authorization evidence. View source
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. doi:10.1056/NEJMoa2032183 View source
